In contrast to the plethora of experiments that almost exclusively centred on developing mTOR inhibitors working in anti-cancer therapy, Sengupta et al. (2019) focus on the mTOR activator needed in the therapy of the central nervous system (CNS) diseases including depression and conditions linked to cognition, learning and memory. Here, MTOR is linked to depressive symptom measurement.